Business Description
Nuformix PLC
ISIN : GB00BYW79Y38
Description
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.94 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.72 | |||||
| Beneish M-Score | 30.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.6 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year FCF Growth Rate | -26 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.06 | |||||
| 9-Day RSI | 1.97 | |||||
| 14-Day RSI | 7.47 | |||||
| 6-1 Month Momentum % | -50 | |||||
| 12-1 Month Momentum % | -75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 1.11 | |||||
| Cash Ratio | 0.73 | |||||
| Days Payable | 10128.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | -36.59 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96 | |||||
| Operating Margin % | -2540 | |||||
| Net Margin % | -2218 | |||||
| FCF Margin % | -330 | |||||
| ROE % | -5.83 | |||||
| ROA % | -5.49 | |||||
| ROIC % | -5.94 | |||||
| 3-Year ROIIC % | 540.41 | |||||
| ROC (Joel Greenblatt) % | -352.17 | |||||
| ROCE % | -5.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.1 | |||||
| EV-to-EBIT | -0.93 | |||||
| EV-to-EBITDA | -0.98 | |||||
| EV-to-Revenue | 4.54 | |||||
| EV-to-FCF | -1.34 | |||||
| Earnings Yield (Greenblatt) % | -107.14 | |||||
| FCF Yield % | -41.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuformix PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.06 | ||
| EPS (TTM) (€) | -0.002 | ||
| Beta | 0.93 | ||
| Volatility % | 69.06 | ||
| 14-Day RSI | 7.47 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 0.0005 | ||
| 12-1 Month Momentum % | -75 | ||
| 52-Week Range (€) | 0.0005 - 0.003 | ||
| Shares Outstanding (Mil) | 819.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuformix PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuformix PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nuformix PLC Frequently Asked Questions
What is Nuformix PLC(STU:1RT)'s stock price today?
The current price of STU:1RT is €0.00. The 52 week high of STU:1RT is €0.00 and 52 week low is €0.00.
When is next earnings date of Nuformix PLC(STU:1RT)?
The next earnings date of Nuformix PLC(STU:1RT) is 2025-01-03 Est..
Does Nuformix PLC(STU:1RT) pay dividends? If so, how much?
Nuformix PLC(STU:1RT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers